TABLE 3

Biodistribution of Radiolabeled MAbs and Tumor-to-Nontumor Organ Ratios in Nude Mice Bearing LNCaP Tumors at 6 Days After Injection

Organ	¹³¹I-J415 (n = 5)	¹³¹I-J591 (n = 8)	¹³¹I-7E11 (n = 8)	¹¹¹In-J415 (n = 4)	¹¹¹In-J591 (n = 8)	¹¹¹In-7E11 (n = 4)
Blood	3.95 ± 0.99^b	4.42 ± 1.74^c	7.13 ± 1.90^bc	2.63 ± 0.47^e	2.52 ± 0.56^f	4.16 ± 0.41^ef
Heart	1.57 ± 0.47^b	1.42 ± 0.60^c	2.46 ± 0.46^bc	1.30 ± 0.10	1.28 ± 0.24	2.42 ± 1.49
Lung	2.61 ± 1.00	2.29 ± 0.91^c	3.52 ± 0.59^c	3.07 ± 0.67	2.47 ± 0.65	3.20 ± 0.16
Liver	1.74 ± 0.91	1.31 ± 0.34^c	2.01 ± 0.49^c	4.69 ± 0.61^d	6.08 ± 0.83^df	4.37 ± 0.46^f
Kidney	1.36 ± 0.62	1.20 ± 0.51	1.65 ± 0.39	4.67 ± 0.45^e	4.53 ± 0.87^f	2.85 ± 0.26^e
Stomach	0.54 ± 0.19	0.47 ± 0.15	0.47 ± 0.23	0.44 ± 0.20	0.46 ± 0.17	0.31 ± 0.07
Small intestine	0.47 ± 0.15	0.35 ± 0.09^c	0.52 ± 0.14^c	0.93 ± 0.04^e	0.84 ± 0.13^f	0.64 ± 0.08^ef
Large intestine	0.30 ± 0.16	0.24 ± 0.07^c	0.38 ± 0.12^c	0.71 ± 0.13	0.57 ± 0.10	0.64 ± 0.06
Muscle	0.30 ± 0.06^b	0.33 ± 0.18^c	0.74 ± 0.31^bc	0.35 ± 0.11	0.30 ± 0.10	0.36 ± 0.08
Thyroid	28.5 ± 13.1	35.1 ± 18.4	29.3 ± 10.6	1.66 ± 0.22^de	0.85 ± 0.36^df	1.38 ± 0.25^ef
Spleen	1.37 ± 0.25	1.74 ± 0.72	1.74 ± 0.38	4.32 ± 1.32	3.36 ± 0.61	3.14 ± 0.60
Tumor	15.4 ± 2.4^a	9.58 ± 3.2^ac	14.5 ± 4.8^c	17.7 ± 3.1	17.4 ± 3.5	18.7 ± 2.2
Tumor/blood	4.49 ± 1.81^ab	2.28 ± 0.77^a	2.21 ± 1.33^b	6.78 ± 0.78^e	6.07 ± 1.79	4.57 ± 0.31^e
Tumor/liver	11.7 ± 5.5	7.21 ± 1.80	7.38 ± 2.40	3.79 ± 0.47^e	3.22 ± 0.52^f	4.33 ± 0.85^ef
Tumor/spleen	9.69 ± 3.73	6.90 ± 2.20	8.89 ± 3.84	4.57 ± 2.33	5.14 ± 0.95	6.52 ± 2.32
Tumor/muscle	56.1 ± 11.2^ab	34.1 ± 15.9^a	21.8 ± 12.9^b	52.1 ± 11.2^d	64.3 ± 5.9^d	55.6 ± 12.8

Data are %ID/g, expressed as mean ± SD. Difference between means in following groups is significant (P < 0.05): (a) ¹³¹I-J415 vs. ¹³¹I-J591; (b) ¹³¹I-J415 vs. ¹³¹I-7E11; (c) ¹³¹I-J591 vs. ¹³¹I-7E11; (d) ¹¹¹In-J415 vs. ¹¹¹In-J519; (e) ¹¹¹In-J415 vs. ¹¹¹In-7E11; (f) ¹¹¹In-J591 vs. ¹¹¹In-7E11.